These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 23271192)

  • 41. Within-subject comparison of striatal D2 receptor occupancy measurements using [123I]IBZM SPECT and [11C]Raclopride PET.
    Catafau AM; Suarez M; Bullich S; Llop J; Nucci G; Gunn RN; Brittain C; Laruelle M;
    Neuroimage; 2009 Jun; 46(2):447-58. PubMed ID: 19233294
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Repeated aripiprazole treatment causes dopamine D2 receptor up-regulation and dopamine supersensitivity in young rats.
    Varela FA; Der-Ghazarian T; Lee RJ; Charntikov S; Crawford CA; McDougall SA
    J Psychopharmacol; 2014 Apr; 28(4):376-86. PubMed ID: 24045880
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The use of healthy volunteers instead of patients to inform drug dosing studies: a [¹¹C]raclopride PET study.
    Kim E; Howes OD; Kim BH; Yu KS; Jeong JM; Lee JS; Kim SJ; Jang IJ; Park JS; Kim YG; Shin SG; Turkheimer FE; Kapur S; Kwon JS
    Psychopharmacology (Berl); 2011 Oct; 217(4):515-23. PubMed ID: 21503604
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of working-memory training on striatal dopamine release.
    Bäckman L; Nyberg L; Soveri A; Johansson J; Andersson M; Dahlin E; Neely AS; Virta J; Laine M; Rinne JO
    Science; 2011 Aug; 333(6043):718. PubMed ID: 21817043
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
    Kapur S; Zipursky RB; Remington G
    Am J Psychiatry; 1999 Feb; 156(2):286-93. PubMed ID: 9989565
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
    Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
    Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cognition and Dopamine D
    Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC; Graff-Guerrero A
    Am J Geriatr Psychiatry; 2017 Jan; 25(1):1-10. PubMed ID: 27745822
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of methylphenidate on regional brain glucose metabolism in humans: relationship to dopamine D2 receptors.
    Volkow ND; Wang GJ; Fowler JS; Logan J; Angrist B; Hitzemann R; Lieberman J; Pappas N
    Am J Psychiatry; 1997 Jan; 154(1):50-5. PubMed ID: 8988958
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology.
    Nørbak-Emig H; Ebdrup BH; Fagerlund B; Svarer C; Rasmussen H; Friberg L; Allerup PN; Rostrup E; Pinborg LH; Glenthøj BY
    Int J Neuropsychopharmacol; 2016 May; 19(5):. PubMed ID: 26819282
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The dopamine stabilizer (-)-OSU6162 occupies a subpopulation of striatal dopamine D2/D3 receptors: an [(11)C]raclopride PET study in healthy human subjects.
    Tolboom N; Berendse HW; Leysen JE; Yaqub M; van Berckel BN; Schuit RC; Ponsen MM; Bakker E; Hoetjes NJ; Windhorst AD; Carlsson ML; Lammertsma AA; Carlsson A
    Neuropsychopharmacology; 2015 Jan; 40(2):472-9. PubMed ID: 25248987
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone.
    Mamo D; Kapur S; Shammi CM; Papatheodorou G; Mann S; Therrien F; Remington G
    Am J Psychiatry; 2004 May; 161(5):818-25. PubMed ID: 15121646
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.
    Nyberg S; Eriksson B; Oxenstierna G; Halldin C; Farde L
    Am J Psychiatry; 1999 Jun; 156(6):869-75. PubMed ID: 10360125
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study.
    Bigliani V; Mulligan RS; Acton PD; Ohlsen RI; Pike VW; Ell PJ; Gacinovic S; Kerwin RW; Pilowsky LS
    Psychopharmacology (Berl); 2000 Jun; 150(2):132-40. PubMed ID: 10907666
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study.
    Gründer G; Fellows C; Janouschek H; Veselinovic T; Boy C; Bröcheler A; Kirschbaum KM; Hellmann S; Spreckelmeyer KM; Hiemke C; Rösch F; Schaefer WM; Vernaleken I
    Am J Psychiatry; 2008 Aug; 165(8):988-95. PubMed ID: 18381901
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Similar striatal D2/D3 dopamine receptor availability in adults with Tourette syndrome compared with healthy controls: A [(11) C]-(+)-PHNO and [(11) C]raclopride positron emission tomography imaging study.
    Abi-Jaoude E; Segura B; Obeso I; Cho SS; Houle S; Lang AE; Rusjan P; Sandor P; Strafella AP
    Hum Brain Mapp; 2015 Jul; 36(7):2592-601. PubMed ID: 25788222
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Savoxepine: striatal dopamine-D2 receptor occupancy in human volunteers measured using positron emission tomography (PET).
    Leenders KL; Antonini A; Thomann R; Locher JT; Maître L; Gerebtzoff A; Beer HF; Ametamey S; Weinreich R; Gut A
    Eur J Clin Pharmacol; 1993; 44(2):135-40. PubMed ID: 8095895
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Modeling of brain D2 receptor occupancy-plasma concentration relationships with a novel antipsychotic, YKP1358, using serial PET scans in healthy volunteers.
    Lim KS; Kwon JS; Jang IJ; Jeong JM; Lee JS; Kim HW; Kang WJ; Kim JR; Cho JY; Kim E; Yoo SY; Shin SG; Yu KS
    Clin Pharmacol Ther; 2007 Feb; 81(2):252-8. PubMed ID: 17259948
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography.
    Hietala J; Syvälahti E; Vuorio K; Någren K; Lehikoinen P; Ruotsalainen U; Räkköläinen V; Lehtinen V; Wegelius U
    Arch Gen Psychiatry; 1994 Feb; 51(2):116-23. PubMed ID: 7905257
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial.
    Nakajima S; Uchida H; Bies RR; Caravaggio F; Suzuki T; Plitman E; Mar W; Gerretsen P; Pollock BG; Mulsant BH; Mamo DC; Graff-Guerrero A
    Schizophr Bull; 2016 Jan; 42(1):212-9. PubMed ID: 26221049
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor.
    Jordan S; Koprivica V; Chen R; Tottori K; Kikuchi T; Altar CA
    Eur J Pharmacol; 2002 Apr; 441(3):137-40. PubMed ID: 12063084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.